Nanoparticle-based drug delivery systems in cancer therapy: A systematic review and meta-analysis

نویسندگان
doi
10.48309/jmpcr.2025.580306.2031
چکیده

Nanoparticle-based drug delivery systems (NDDS) have garnered substantial scientific and clinical interest as alternatives to conventional oncological therapies, which remain constrained by systemic toxicity, inadequate tumour targeting, and poor pharmacokinetic profiles. The present review sought to evaluate the comparative efficacy and safety of nanoparticle-based drug delivery systems against conventional cancer therapies, and to perform a rigorous meta-analysis estimating pooled effect sizes for overall response rate, overall survival, and progression-free survival across multiple cancer types and nanoparticle platforms. A systematic search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library was conducted for studies published between January 2021 and January 2025. Studies were included if they enrolled human patients with diagnosed malignancies, evaluated at least one defined nanoparticle platform against a conventional comparator, and reported quantitative outcome data. Meta-analysis was performed using a random-effects model. A total of 22 studies encompassing 3,419 participants met the inclusion criteria, of which 18 provided sufficient quantitative data for meta-analysis. The pooled odds ratio for overall response rate significantly favoured nanoparticle-based delivery over conventional therapy (OR = 2.18; 95% CI: 1.87 to 2.54; p < 0.001). Overall survival was meaningfully prolonged in the NDDS groups (pooled HR = 0.72; 95% CI: 0.63 to 0.82; p < 0.001), representing a 28% reduction in the hazard of death. Regarding safety, grade 3 or 4 adverse events were substantially reduced across all nanoparticle categories: haematological toxicity (RR = 0.59; 95% CI: 0.48 to 0.72; p < 0.001), nausea and vomiting (RR = 0.62; 95% CI: 0.51 to 0.76; p < 0.001), peripheral neuropathy (RR = 0.52; 95% CI: 0.40 to 0.67; p < 0.001), and cardiotoxicity (RR = 0.43; 95% CI: 0.28 to 0.66; p < 0.001). Liposomal formulations demonstrated the most consistent clinical benefit, whilst metallic and polymeric nanoparticles showed promising but more heterogeneous effects. Nanoparticle-based drug delivery systems confer statistically significant and clinically meaningful improvements in tumour response (OR 2.18), survival (HR 0.72), and tolerability compared with conventional therapies across a range of solid malignancies.